Pediatric Cholestatic Diseases in the Era of Ileal Bile Acid Transporter (IBAT) Inhibitors
Open Access
- 3 February 2026
- journal article
- review article
- Published by MDPI AG in Pediatric Reports
- Vol. 18 (1) , 19
Abstract
Cholestatic diseases in children represent a heterogeneous group of disorders that, with few exceptions, have no cure. For decades, off-label drugs and/or drugs with little evidence of efficacy have been used to treat pruritus or as supportive therapy. In recent years, a family of molecules known as bile acid transporter inhibitors (IBATis) has been developed, with two of these being approved for treating pruritus in progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). Blocking the ileal reabsorption of bile acids (BAs) lowers serum levels. This contributes to reducing cholestatic pruritus. Such a mechanism of action may also have a potential benefit in other cholestatic diseases and even in the consequences of chronic cholestasis. This is a narrative review of the literature, including the most recent communications, to summarize data on the efficacy and safety of IBATis in the treatment of pruritus in PFIC and ALGS in children, including a description of the latest results from their use in a real-world setting. Reports on off-label use and experiences in adults are also discussed. This review aims to help physicians understand the potential and limitations of these new drugs in the treatment of cholestatic pruritus.Keywords
This publication has 87 references indexed in Scilit:
- Serum bile acids as a prognostic biomarker in biliary atresia following Kasai portoenterostomyHepatology, 2023
- Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA studyHepatology, 2022
- European Liver Transplant Registry: Donor and transplant surgery aspects of 16,641 liver transplantations in childrenHepatology, 2021
- Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 DeficiencyHepatology, 2021
- Outcomes of surgical management of familial intrahepatic cholestasis 1 and bile salt export protein deficienciesHepatology Communications, 2018
- Phenotypic spectrum and diagnostic pitfalls of ABCB4 deficiency depending on age of onsetHepatology Communications, 2018
- MYO5B mutations cause cholestasis with normal serum gamma‐glutamyl transferase activity in children without microvillous inclusion diseaseHepatology, 2017
- Pharmacological inhibition of apical sodium‐dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout miceHepatology, 2015
- Features of Alagille Syndrome in 92 Patients: Frequency and Relation to PrognosisHepatology, 1999
- Ursodeoxycholic Acid Therapy in Pediatric Patients With Progressive Familial Intrahepatic CholestasisHepatology, 1997